Postmenopause Clinical Trial
Official title:
An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of Clinical and Commercial Formulations of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women
The purpose of this clinical trial is to study the blood levels of a drug (conjugated estrogens) in the body from one dosage form compared to another. The four formulations of the study drug that eligible participants will receive will contain the same amounts of the same medications. In addition, information will also be obtained regarding the safety and tolerability of the formulations given to healthy postmenopausal women.
Status | Completed |
Enrollment | 0 |
Est. completion date | November 2007 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 35 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Postmenopausal women aged 35 to 70 years. - Spontaneous or surgical amenorrhea for at least 6 months. - Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight greater than or equal to 50 kg. Exclusion Criteria: - Hypertension or elevated supine blood pressure (>139 mm Hg systolic or >89 mm Hg diastolic). - History of any clinically important drug allergy. - Use of any prescription or investigational drug within 30 days before test article administration. |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Wyeth is now a wholly owned subsidiary of Pfizer |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The plasma concentration data and pharmacokinetic (PK) parameters of BZA and CE. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05448079 -
The Effect of Sexual Counseling Given According to the PLISSIT Model on FSFI, MAS and SQOL-F of Postmenopausal Women
|
N/A | |
Completed |
NCT00745173 -
Study Evaluating Premarin and Bazedoxifene Potential Interaction
|
Phase 1 | |
Completed |
NCT00913926 -
Effects of Wellnara on Climacteric Symptoms
|
N/A | |
Completed |
NCT00381251 -
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
|
Phase 1 | |
Completed |
NCT00515593 -
PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
|
N/A | |
Completed |
NCT00185328 -
Efficacy and Tolerability of Angeliq in Thai Women
|
Phase 4 | |
Completed |
NCT00484107 -
Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women
|
Phase 4 | |
Completed |
NCT00023543 -
Reduction of Triglycerides in Women on Hormone Replacement Therapy
|
Phase 2 | |
Completed |
NCT00006407 -
Sex Steroid Hormones and Risk of CHD in Women
|
N/A | |
Completed |
NCT00152282 -
A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women
|
Phase 2 | |
Completed |
NCT00010712 -
Effects of Black Cohosh on Menopausal Hot Flashes
|
Phase 2 | |
Completed |
NCT00006539 -
Thrombotic, Inflammatory & Gene Markers of CVD in Women
|
N/A | |
Completed |
NCT00005515 -
Mutations, Hormone Therapy (HRT) and Venous Thromboembolism
|
N/A | |
Completed |
NCT00001752 -
Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women
|
Phase 2 | |
Completed |
NCT00000481 -
Women's Health Trial: Feasibility Study in Minority Populations
|
Phase 3 | |
Completed |
NCT00000466 -
Postmenopausal Estrogen/Progestin Interventions (PEPI)
|
Phase 3 | |
Completed |
NCT00543634 -
Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT06115577 -
Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes
|
||
Completed |
NCT01556737 -
Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women
|
N/A | |
Completed |
NCT00455741 -
Postmenopausal Women Estrogen and Progesterone Infusion
|
Phase 1/Phase 2 |